Natus Medical Incorporated (NASDAQ:BABY) – Investment analysts at William Blair issued their Q4 2018 earnings per share estimates for Natus Medical in a report issued on Monday. William Blair analyst B. Weinstein forecasts that the medical equipment provider will earn $0.65 per share for the quarter.
A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded Natus Medical from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. BidaskClub upgraded Natus Medical from a “sell” rating to a “hold” rating in a research report on Saturday, July 1st. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. Natus Medical has an average rating of “Hold” and an average price target of $45.00.
COPYRIGHT VIOLATION WARNING: This report was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/09/13/brokers-issue-forecasts-for-natus-medical-incorporateds-q4-2018-earnings-baby.html.
Shares of Natus Medical (BABY) traded down 1.24% during trading on Wednesday, reaching $35.90. The company’s stock had a trading volume of 131,963 shares. Natus Medical has a 12-month low of $31.65 and a 12-month high of $44.39. The stock’s 50-day moving average is $34.07 and its 200-day moving average is $36.13. The stock has a market cap of $1.17 billion, a P/E ratio of 62.22 and a beta of 0.96.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The company had revenue of $122.20 million during the quarter, compared to analysts’ expectations of $121.99 million. During the same quarter in the previous year, the firm earned $0.39 EPS. Natus Medical’s revenue was up 27.3% on a year-over-year basis.
In related news, insider James B. Hawkins acquired 4,000 shares of the firm’s stock in a transaction dated Thursday, June 15th. The shares were purchased at an average price of $33.98 per share, for a total transaction of $135,920.00. Following the completion of the acquisition, the insider now owns 578,023 shares in the company, valued at $19,641,221.54. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director William M. Moore sold 3,000 shares of Natus Medical stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $34.10, for a total value of $102,300.00. Following the completion of the transaction, the director now owns 30,410 shares in the company, valued at approximately $1,036,981. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in BABY. BlackRock Inc. grew its stake in shares of Natus Medical by 137,510.8% in the first quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock worth $161,874,000 after purchasing an additional 4,121,198 shares during the last quarter. Columbia Wanger Asset Management LLC grew its stake in shares of Natus Medical by 243.6% in the first quarter. Columbia Wanger Asset Management LLC now owns 2,030,207 shares of the medical equipment provider’s stock worth $79,686,000 after purchasing an additional 1,439,382 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Natus Medical by 105.7% in the first quarter. Wellington Management Group LLP now owns 1,795,094 shares of the medical equipment provider’s stock worth $70,457,000 after purchasing an additional 922,268 shares during the last quarter. Koch Industries Inc. grew its stake in shares of Natus Medical by 7,423.5% in the second quarter. Koch Industries Inc. now owns 462,472 shares of the medical equipment provider’s stock worth $450,000 after purchasing an additional 456,325 shares during the last quarter. Finally, Epoch Investment Partners Inc. grew its stake in shares of Natus Medical by 68.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,110,932 shares of the medical equipment provider’s stock worth $43,604,000 after purchasing an additional 450,698 shares during the last quarter. Hedge funds and other institutional investors own 92.65% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.